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Rezumat. În Moldova nu există precedent în producerea biosimilarelor. Elucidarea structurii biochimice și clonarea 
genei hormonului de creștere uman (hGH) au dus la dezvoltarea farmaceutică a rhGH la mijlocul anilor 1980 în SUA. 
Odată cu expirarea perioadei de protecţie a brevetului pentru hGH de referinţă, a apărut oportunitatea dezvoltării 
produselor medicamentoase biosimilare. Proiectul de inovare și transfer tehnologic „Procedeu de cultivare a ma-
teriei prime pe bază de Pichia pastoris cu expresia hormonului de creștere” a demarat în ianuarie 2021, în cadrul 
Universităţii de Stat de Medicină și Farmacie „Nicolae Testemiţanu”, Centrul Știinţific al Medicamentului din Repu-
blica Moldova. Proiectul este finanţat de Agenţia Naţională pentru Cercetare și Dezvoltare din Moldova, iar cofinan-
ţator este Întreprinderea Farmaceutică Balkan Pharmaceuticals. Scopul proiectului este transferul tehnologic al 
procedeului de cultivare a vectorului Pichia pastoris cu expresia hGH: crearea băncii de celule de lucru, prepararea 
inoculului și creșterea culturii Pichia pastoris, precum și elaborarea documentaţiei aferente acestor activităţi. Fa-
bricarea autohtonă a rhGH oferă un avantaj farmacoeconomic deosebit faţă de concurentul existent astăzi pe piaţa 
Republicii Moldova - Saizen® pulbere pentru soluţie injectabilă, Ares Trading SA, Elveţia (producător Merck Serono 
SPA, Italia). 
Cuvinte cheie: biosimilar, rhGH, transfer tehnologic, cultura Pichia pastoris, bancă de celule de lucru.
Summary. In Moldova there is no precedent in biosimilars production. Elucidation of the biochemical structure 
and cloning of the hGH gene led to the pharmaceutical development of rhGH in the mid-1980s in the USA. With 
the expiry of patent protection period of the reference hGH, the opportunity arose for the development of biosi-
milar medicinal products. The project for innovation and technology transfer “Cultivation process of raw material 
based on Pichia pastoris with the expression of growth hormone” has started in January 2021, within the State 
University of Medicine and Pharmacy “Nicolae Testemitanu”, the Scientific Center of Medicine from Republic of 
Moldova. The project is funded by the National Agency for Research and Development from Moldova and co-fi-
nancier is the Pharmaceutical Enterprise Balkan Pharmaceuticals. The overall goal of the project is the technology 
transfer of cultivation process of the vector Pichia pastoris with the expression of hGH: creation of working cell 
bank, preparation of inoculum and growth of Pichia pastoris culture, and elaboration of documentation related to 
these activities. The local manufacture of the rhGH offers an incomparable pharmacoeconomic advantage over 
the competitor existing today on the market of Republic of Moldova - Saizen® powder for injection solution, Ares 
Trading SA, Switzerland (manufacturer Merck Serono S.P.A., Italy).
Keywords: biosimilar, rhGH, technological transfer, Pichia pastoris culture, working cell bank.
 INTRODUCTION
The EMA defines a biosimilar as “a biological medicinal 
product that contains a version of the active substan-
ce of an already authorized original biological medicinal 
product (reference medicinal product) in the European 
Economic Area (EEA). Similarity to the reference medici-
nal product in terms of quality characteristics, biological 
activity, safety and efficacy based on a comprehensive 
comparability exercise needs to be established”. The pio-
neer of this drug class is Omnitrope® (Somatropin) and it 
was approved by the European Medicines Agency (EMA) 
in 2006. Since 2006, several general and product-speci-
fic biosimilar guidelines were developed by the EMA and 
it is mandatory to mention that EU was the first region 
in the world to develop a legal, regulatory, and scientific 
framework for approving biosimilar medicines. In compa-
rison the first biosimilar was approved in the USA only in 
2015. To date, EMA has recommended the approval of 77 
biosimilars within the product classes of: 1) human growth 
hormone; 2) granulocyte colony-stimulating factor; 3) 
erythropoiesis stimulating agent; 4) insulin; 5) follicle-sti-
mulating hormone (FSH); 6) parathyroid hormone; 7) tu-
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mour necrosis factor (TNF)-inhibitor; and 8) monoclonal 
antibodies [1]. 
Pharmaceutical enterprises worldwide have at least 
three good reasons to move to a biologics-oriented in-
dustry. Firstly, the distinctive capability of biologics to 
bind with target sites that are difficult to achieve or even 
inaccessible to small molecule drugs which is mainly due 
to protein-protein interactions that involve flat surfaces 
with fewer charged regions. Secondly, another attractive 
feature of biologics consists in its most auspicious com-
mercial potential [2]. It is estimated that around $194 bi-
llion worth sales of biologics are at risk in the period be-
tween 2017 and 2022. This anticipates the beginning of 
another patent cliff era of blockbuster biologic drug pro-
ducts being challenged by biosimilars. Thirdly, the overall 
economic return assured by biologics is significantly hi-
gher than that of small molecule drugs.
The expiration of the term of patent protection (gene-
rally this period is 20 years from the date of filing the rele-
vant patent application) of the original biosimilar products 
is a key factor in the decision of companies to develop 
biosimilars [3]. Most innovators also depend on supple-
mentary protection certificates (SPCs), that represents 
the intellectual property right that serves as a five years’ 
extension to the patent right, and data exclusivity to ex-
tend the term of protection. The European Commission 
recently issued a proposal to amend the rules on SPCs to 
include “Waiver of export production” to third parties for 
patented products, in order to promote the competitive-
ness of generic and biosimilar industries in global markets. 
This change may encourage the expansion of the market 
and the export of locally manufactures biosimilars [4].
Because it is by definition easier to reproduce than 
to generate a product de novo, biosimilar has a higher 
chance of conquering the market and denotes fewer 
pharmacoeconomic risks than the reference biological 
products. In addition, investments in original biologic pro-
ducts are incomparably higher than in the case of biosi-
milar products, with a much lower chance of success [5]. 
Reports from the research and development departments 
of pharmaceutical companies show that about 95% of all 
drug projects never reach the market. The investments 
needed to develop and market a biosimilar is considerably 
larger than the amount between $ 1 million and $ 4 million 
attributable to generic drugs [6]. Between 7 and 8 years at 
a cost of between 100 and 250 million dollars is needed to 
develop a biosimilar. However, IMS Health estimates that 
the use of biosimilars has resulted in savings of up to € 
100 billion in the United States (US) and the five major Eu-
ropean Union (EU) countries by 2020.
DISCUSSIONS
Biologics manufacture involves a fundamentally diffe-
rent approach from traditional chemical synthesis. Invol-
ving living systems makes nearly impossible following an 
exact science as chemistry. The design of complex mul-
tistep processes utilizing mammalian and microbial cell 
cultures brings to life the paradigm of the biologic manu-
facturing process “The process is the product”. Conven-
tional preparation process of biologics assumes sequen-
tial steps like desired gene isolation, insertion into vector, 
expression of host cell, cell culture, cell bank creation 
and characterization, production of protein, purification 
of protein, analysis and finally formulation. The biosimilar 
development process unfolds based on several strategic 
considerations [7]:
(1) Defining the target—This involves detecting any 
variability in the reference target molecule and any 
corresponding changes in qualitative properties of 
the drug. 
(2) Development based on target—The engineering 
process of the biosimilar is designed to match the 
criteria of the reference, including factors like cho-
ice of cell line, biological processes, and others.
(3) Similarity confirmation of the biosimilar—Degree of 
biosimilarity with the reference assessed via phy-
sical, chemical, and biological analyses of the bio-
similar.
(4) Regulatory authorization—Co-operating with re-
levant regulatory authorities to determine the mi-
nimum amount of clinical information required for 
biosimilarity approval.
(5) Clinical assessment—Conducting clinical trials to 
confirm biosimilarity and compiling any other in-
formation required for commercialization of the 
biosimilar.
Biosimilars face a more stringent regulatory assess-
ment than generics, including the need for clinical trials, 
which significantly increases costs and timelines to mar-
ket entry of biosimilars. Establishing appropriate standar-
ds for biosimilarity remains one of the main and the most 
prolific topics for scientific, legislative, and regulatory 
debate. There are five generally accepted starting points 
fundamental to the assessment of biosimilar products: 
(1) we cannot try on the generics template for biosi-
milars, therefore the approach should be individual 
and specific to this drug class;
(2) similarity should be assessed in terms of quality, 
safety, efficacy;
(3) a step-wise comparability approach that proves 
the similarity of the similar to reference product in 
terms of quality is a prerequisite for the reduction 
of nonclinical and clinical data submitted; 
(4) the assessment of each biosimilar is based on a ca-
se-by-case approach;
(5) the importance of pharmacovigilance is stressed. 
At first sight, the process of assessing the biosimilarity 
of products is similar to that of assessing bioequivalence 
for generic medicinal products. If the development of a 
generic focuses on the demonstration of bioequivalence, 
then in order to demonstrate biosimilarity, a series of com-
parability studies are carried out aiming at juxtaposition 
of each characteristic of the biosimilar medicinal product 
with that of the reference medicinal product. The process 
includes endpoint selection; biosimilarity criteria; study 
design; statistical methods for data analysis [8]. Biosimilar 




products are obtained from living cells or organisms with 
mixed, complicated structures that are difficult, if not im-
possible, to fully characterize. Thus, standard methods 
for assessing the bioequivalence of generic small mole-
cule medicinal products cannot be properly and directly 
applied to assess biosimilarity.
The studies performed for demonstrating pharmace-
utical quality must provide detailed data on: structural 
characterization and other physicochemical properties; 
purity (traces of residues resulting from the manufac-
turing process must be controlled and must not exce-
ed acceptable levels); biological activity; excipients and 
raw materials; concentration and pharmaceutical form; 
control of the manufacturing process (in order to ensure 
compliance of the active substance and the finished me-
dicinal product within the accepted intervals for the tech-
nical specifications);the stability of the active substance 
and the finished medicinal product during the shelf life, 
under the defined storage conditions [15].  It is known that 
biosimilar products are sensitive to environmental fac-
tors, such as light and temperature, and a minor change 
or variation in any critical stage of the manufacturing pro-
cess could lead to a drastic change in clinical outcomes.
Factors influencing the number and types of clinical 
trials to be performed include: molecule complexity and 
available comparability data, availability of a final efficacy 
pharmacodynamic evaluation criterion, safety profile of 
the reference drug or pharmacological class, potential for 
immunogenicity, the possibility of extrapolation to other 
indications.
In case the originally authorized medicinal product has 
more than one indication, the efficacy and safety of bi-
osimilar must be justified or demonstrated separately 
for each of the therapeutic indications [14]. At least one 
comparative trial (efficacy and safety) in a “sensitive” po-
pulation with relevant clinical endpoints should be held. 
It is possible the extrapolation to other indications of the 
reference product, not studied during the development of 
biosimilar, based on the overall evidence of comparability. 
The acceptance of indications extrapolation is decided on 
a case-by-case basis, depending on the strength of sci-
entific demonstration of comparability. 
Although doctors can confidently use biologics in all 
their approved indications, assuming that they are given 
based on scientific evidence, the reference to the princi-
ple of extrapolation can only be made after sound com-
parability studies. Comparability is designed as a step-
by-step process, tailored to each drug; stage 1 comprises 
the knowledge gained from initial quality comparability 
studies that are used to determine the extent and type of 
non-clinical (stage 2) and clinical (stage 3) studies requ-
ired in the next stage of development, always aiming to 
rule out clinical performance differences between the bi-
osimilar and the reference medicine.
In terms of interchangeability, the intervention of both 
medical practitioners and healthcare authorities is nee-
ded. Interchangeability refers to the possibility of repla-
cing one drug with another that is expected to have the 
same clinical effect [9]. The decision to allow interchan-
geable use and substitution of the reference biological 
medicine with the biosimilar one shall be taken at natio-
nal level. Starting from the existing legal framework, the 
respective regulations, guidelines and recommendations 
are issued. As with any medication, healthcare professio-
nals must choose carefully when prescribing, considering 
the patient’s medical history. Therefore, any decision to 
replace a medicinal product with another medicinal pro-
duct that has the same indication should be taken by the 
physician in consultation with the patient considering 
possible national policies on the prescription and use of 
biologic medicinal products. Reimbursement of biosimi-
lars instead of originators, more national bodies dedicated 
to biosimilars, the reassuring data from switching studies, 
increased awareness of health professionals, a growing 
number of publications confirming the clinical similarity 
of biosimilars with originators and finally the accumulated 
positive clinical experience with biosimilars speak in favor 
of the increasing confidence in biosimilars [10].
In Moldova there is no precedent in biosimilars pro-
duction. In March 2013, the order on the introduction of 
good manufacturing practice (GMP) came into force. As 
a result, only 16 of the 28 existing pharmaceutical com-
panies remained. Currently Moldovan manufacturers pro-
duce over 400 generic drugs, it is the main and in fact the 
only focus of the domestic pharmaceutical industry. The 
local manufacture of the biosimilars obviously would offer 
an incomparable pharmacoeconomic advantage over all 
the existing and potential competitors.
Local biosimilars production involves reducing the 
time and costs for developing internal know-how and the 
prospect of creating contagion effects in other areas, in-
cluding access to wider distribution networks and new 
business opportunities [13]. Consistent is the reduction of 
state budget expenditures for the acquisition of biosimi-
lars and the redirection of resources to the development 
and implementation of national health programs. Broa-
dening the profile of local pharmaceutical plants implies 
the emergence of new jobs. An inconceivable advantage 
is the increase of the production volume and the turnover 
of the national pharmaceutical industry through the ex-
port of biosimilars, the increase of the sales market. Ma-
nufacturing biosimilars in Republic of Moldova represents 
an excellent opportunity for increasing the operating pro-
fit margin for local manufacturers, for traditional generic 
drugs it’s roughly 20, but for biosimilars around 30. That 
goes without saying that reputational benefits cannot be 
ignored.
Somatropin is a polypeptide consisting of 191 amino 
acids, by composition and chemical structure it is iden-
tical to human growth hormone of pituitary origin in ter-
ms of consistency and composition, as well as the map 
of peptides, isoelectric point, molecular mass, isomeric 
structure and biological activity. The first data confirming 
the effectiveness of human growth hormone (rhGH) were 
obtained in 1958, just 2 years after its isolation from the 
human pituitary gland. However, before the development 
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of recombinant DNA technology, hGH for the purpose of 
substitution therapy could only be obtained by extraction 
and purification from human cadaveric pituitary glands. 
Therefore, the market supply was very low and hGH re-
placement therapy was reserved only for the most severe 
cases of growth hormone deficiency (GHD). Elucidation 
of the biochemical structure and cloning of the hGH gene 
led to the pharmaceutical development of recombinant 
human growth hormone (rhGH) in the mid-1980s in the 
United States. With the expiry of the period of protecti-
on of the reference medicinal product on the market, the 
opportunity arose for the development of biosimilar me-
dicinal products. 
Omnitrope® (biosimilar rhGH; Sandoz, Kundl, Austria) 
approved by EMA in 2006, has since been approved worl-
dwide, including in the US, and the product is now avai-
lable in over 50 countries. Since its launch, more than 
40.000 patients have been treated with biosimilar rhGH, 
generating a total experience of almost 107 million days 
of inpatient treatment [11]. The appearance of an abun-
dant amount of rhGH allowed the treatment of several 
children, later and adults, as well as the extension of the 
area of  therapeutic indications. RhGH is currently indi-
cated in growth retardation in children due to reduced 
or lack of secretion of endogenous growth hormone or 
chronic renal failure, in case of gonadal dysgenesis (Tur-
ner syndrome), growth disorders in children born small for 
gestational age (SGA), and in adults in the accentuated 
growth hormone deficiency, also in severe burns. 14 years 
on the European market for the first biosimilar rhGH may 
be characterized by the absence of unexpected or unique 
adverse events, the absence of signs of increased risk of 
cancer or glucose homeostasis disorder compared to the 
reference biological medicine and other rhGH products, 
and the immunogenicity of biosimilar rhGH is, also similar 
to that of other products in that class [12].
Currently on the market of Republic of Moldova only 
one medicinal product from the group of anterior pituitary 
lobe hormones is authorized, namely Saizen®, powder and 
solvent for injection solution, 8 mg, marketing authoriza-
tion holder Ares Trading SA, Switzerland, manufacturer 
Merck Serono S.P.A., Italy. Thus, we can conclude that the 
domestic pharmaceutical market does not face the phe-
nomenon of competition regarding medicinal products 
from the ATC group H01AC01. Because rhGH medical 
therapy usually has a recommended duration of several 
years and an individualized dosing regimen with a dose 
calculation based on the patient’s body weight, a priority 
issue is to increase patient adherence and adherence to 
treatment. 
The project for innovation and technology transfer 
“Cultivation process of raw material based on Pichia pas-
toris with the expression of growth hormone”, with re-
gistration number 21.80015.8007.244T has started in Ja-
nuary 2021, within the State University of Medicine and 
Pharmacy “Nicolae Testemitanu”, the Scientific Center of 
Medicine from Republic of Moldova. The project is funded 
by the National Agency for Research and Development 
from Republic of Moldova and co-financier is the Pharma-
ceutical Enterprise Balkan Pharmaceuticals, Republic of 
Moldova.    
The project has the following objectives:
	 perform the technological transfer for the manufac-
turing process of a new biosimilar rhGH product and 
improve the innovation capacity of pharmaceutical 
manufacturer Balkan Pharmaceuticals; 
	 obtain scientific results during the technological 
transfer process; 
	 improve the collaboration among the co-financier 
Pharmaceutical manufacturer Balkan Pharmaceuti-
cals, the scientific research institutes and the Nati-
onal Agency for Research and Development of the 
Republic of Moldova;  
	 increase the capacity of assimilation into manu-
facturing process of the research results obtained 
during the project; 
	 create the WCB (working cell bank) of Pichia pastoris 
culture for short and long term storage, with sub-
sequent inoculum preparation and growth of Pichia 
pastoris culture with rhGH expression.
The final result of the project is the technology transfer 
of cultivation process of the vector Pichia pastoris with 
the expression of rhGH: creation of working cell bank, pre-
paration of inoculum and growth of Pichia pastoris cul-
ture, and elaboration of documentation related to these 
activities.
The excellence of the project consists not only in the 
manufacture of the first biosimilar in the Republic of Mol-
dova - an exhaustive goal in itself, but also in the unpre-
cedented production of recombinant human growth 
hormone (rhGH) in Republic of Moldova. This ensures 
the empirical exploration of the most promising segment 
of the global pharmaceutical industry with the fastest 
growth rate. The realization of the project will involve the 
endowment of the local plant with appropriate equipment 
and machinery and improving the manufacturing facili-
ties, implementing
highly performant analytical and control methods as well 
as increasing employees’ qualification. Per se the field of 
biosimilars is eminently boundless for various local and in-
ternational scientific researches in the huge range of the 
disciplines of medicine and pharmacy.   
The relevance of the project “Cultivation process of 
raw material based on Pichia pastoris with the expression 
of growth hormone” is ensured by: 
	 strengthening the innovation capacity of the bene-
ficiary economic agent (project co-financier) and in-
creasing the product portfolio;
	 obtaining in perspective a new biosimilar product, 
corresponding to regulation requirements in the 
field of biological medicinal products for human use; 
	 the implementation of a biosimilar rhGH in the ma-
nufacturing of the project co-financier who is at the 
same time the beneficiary of the results obtained 
from the research activity;




	 the novelty resulting from the complexity of biosi-
milar cultivation methods, and complex analytical 
testing, using high performance methods and hi-
gh-technological equipment for Pichia pastoris cul-
ture; 
	 obtaining a working cell bank and the cultivation of 
Pichia pastoris with the expression of rhGH for the 
first time in Republic of Moldova; 
	 partners who have specialists and necessary equip-
ment for the documentation works and implemen-
tation into manufacturing process of the new elabo-
rated technologies.
 The implementation of the project “Cultivation pro-
cess of raw material based on Pichia pastoris with the ex-
pression of growth hormone” involves the development 
of activities in the frontier fields: biochemistry, genetics, 
pharmaceutical chemistry, pharmaceutical technology, 
pharmacology, clinical medicine. The activities in the pro-
ject are supported by the partnership with a university 
and a research center, involving specialists in several fiel-
ds: chemistry, biology, genetics, biochemistry, pharmacy, 
medicine, computer science. The results of the interdisci-
plinary collaboration will be documentation works, scien-
tific research, cultivation and conditioning technologies, 
genetic studies, technological production regulations, 
compartments of the authorization documentation, whi-
ch will demonstrate the multidisciplinary character of the 
proposed topic. 
The local manufacture of the rhGH obviously offers an 
incomparable pharmacoeconomic advantage both over 
the only competitor existing today on the market of Re-
public of Moldova - Saizen® and over the potential ones.
Given that recombinant human growth hormone 
(rhGH) is purchased from the state budget according to 
the criterion - at the lowest price without VAT, in accor-
dance with all requirements, including national registrati-
on in the State Nomenclature of Medicines of the Republic 
of Moldova, the priority of the domestic product is obvious 
based only on the classic formula of price calculation by 
summing the cost price and the manufacturer’s margin. 
The realization of the project “Cultivation process of 
raw material based on Pichia pastoris with the expression 
of growth hormone” involves the establishment of part-
nership and collaboration relations with the most impor-
tant and promising players worldwide on the biosimilars 
market.  
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